Crystals
    3.
    发明授权
    Crystals 失效
    晶体

    公开(公告)号:US07309710B2

    公开(公告)日:2007-12-18

    申请号:US10525709

    申请日:2003-08-26

    IPC分类号: A61K31/4439 C07D401/12

    CPC分类号: C07D401/12

    摘要: Obtaining the crystal of 4,6-dimethyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having excellent activity of inhibiting Ca2+ release-activated Ca2+ channel and suppressing IL-2 production to find that the compound includes the presence of two types of polymorphic crystals and that any of the crystals is preferable as a raw material for producing pharmaceutical compositions.

    摘要翻译: 获得具有优异的抑制Ca 2+释放激活活性的4,6-二甲基-4' - [3,5-双(三氟甲基)-1H-吡唑-1-基]烟酰苯胺的结晶 Ca 2+通道并抑制IL-2产生,发现该化合物包括两种类型的多晶型晶体的存在,并且任何晶体优选作为制备药物组合物的原料。

    Novel crystals
    6.
    发明申请
    Novel crystals 失效
    新颖的水晶

    公开(公告)号:US20060069130A1

    公开(公告)日:2006-03-30

    申请号:US10525709

    申请日:2003-08-26

    IPC分类号: A61K31/4439 C07D403/02

    CPC分类号: C07D401/12

    摘要: Obtaining the crystal of 4,6-dimethyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having excellent activity of inhibiting Ca2+ release-activated Ca2+ channel and suppressing IL-2 production to find that the compound includes the presence of two types of polymorphic crystals and that any of the crystals is preferable as a raw material for producing pharmaceutical compositions.

    摘要翻译: 获得具有优异的抑制Ca 2+释放激活活性的4,6-二甲基-4' - [3,5-双(三氟甲基)-1H-吡唑-1-基]烟酰苯胺的结晶 Ca 2+通道并抑制IL-2产生,发现该化合物包括两种类型的多晶型晶体的存在,并且任何晶体优选作为制备药物组合物的原料。